Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN15505 · 1 trial · 2 indications
Dose Escalation
Dose Escalation
Dose Escalation
Dose Escalation
Dose Expansion-mCRPC
Dose Expansion-ccRCC
| Arm | Type | Description |
|---|---|---|
| Module 1: Monotherapy | EXPERIMENTAL | REGN15505 |
| Module 2: Combination 1 | EXPERIMENTAL | REGN15505 and Cemiplimab |
| Module 3: Combination 2 | EXPERIMENTAL | REGN15505 and REGN4336 |
| Name | Type | Description |
|---|---|---|
| REGN15505 | DRUG | Administered per protocol |
| REGN15505+Cemiplimab | DRUG | Administered per protocol |
| REGN15505+REGN4336 | DRUG | Administered per protocol |
Key Inclusion Criteria: Participants with mCRPC: 1. Men with histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma 2. mCRPC with PSA value at screening ≥4 ng/mL and that has progressed within 6 months prior to screening as described in the proto...
REGN15505 is an investigational small molecule being developed by Regeneron Pharmaceuticals for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC). It is currently in Phase 1 clinical development and is not yet approved by the FDA.
REGN15505 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol REGN. The drug is currently in Phase 1 clinical trials for metastatic castration-resistant prostate cancer and clear cell renal cell carcinoma.
REGN15505 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA and is still being studied in clinical trials. The drug is being evaluated for safety and efficacy in patients with metastatic castration-resistant prostate cancer and clear cell renal cell carcinoma.
REGN15505 is being studied in a Phase 1 clinical trial with the identifier NCT07594106. This trial is recruiting participants in the United States and is evaluating REGN15505 alone or in combination with cemiplimab or REGN4336 in adult patients with metastatic castration-resistant prostate cancer and clear cell renal cell carcinoma.
Yes, REGN15505 is also known as PSMAx4-1BB, as indicated in the clinical trial title. The drug is being studied for its potential to target PSMA and 4-1BB pathways in the treatment of metastatic castration-resistant prostate cancer and clear cell renal cell carcinoma.